Thyrocare Technologies Limited Earnings Summary — Q3 FY2026
Thyrocare Technologies Reports Substantial Profit Growth Amidst Capital Restructuring and Bonus Issue
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 3 consecutive quarters.
- Revenue of ₹240 Cr is 24.3% higher year-on-year.
- Revenue has compounded at 21.7% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit has reached its highest level in 10 quarters.
- Net profit of ₹52 Cr is 34.1% above the same quarter last year.
- Profit growth is outpacing revenue growth, pointing to positive operating leverage.
- Net profit has compounded at 61.4% annualised across the period.
- Operating margin stands at 32.2% in Q1 FY2027.
- Operating margin expanded by 226 bps year-on-year.
- Over the last two years operating margin has expanded by 524 bps.
- PBT margin is 28.4%.
- Expense growth of 20.3% remained below revenue growth of 24.3%.
- Operating profit of ₹77 Cr is 33.8% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 81/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 240 | 224 | 196 | 217 | 193 | 187 | 166 | 177 | 157 | 154 |
| Expenses | Improving | 163 | 149 | 138 | 145 | 135 | 130 | 124 | 129 | 115 | 121 |
| Operating Profit | Improving | 77 | 75 | 58 | 71 | 58 | 57 | 42 | 48 | 42 | 34 |
| Operating Margin | Improving | 32.2% | 33.5% | 29.6% | 33.0% | 29.9% | 30.5% | 25.1% | 27.1% | 26.9% | 21.8% |
| Other Income | Volatile | 5 | 5 | -1 | 3 | 5 | 5 | 4 | 3 | 4 | 3 |
| Interest | Volatile | 1 | 2 | -0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | Accelerating | 12 | 14 | 22 | 12 | 11 | 14 | 17 | 13 | 11 | 13 |
| Profit Before Tax | Strong Uptrend | 68 | 64 | 35 | 63 | 50 | 47 | 28 | 37 | 34 | 23 |
| Tax | Volatile | 17 | 16 | 7 | 15 | 12 | 26 | 9 | 10 | 10 | 6 |
| Net Profit | Strong Uptrend | 52 | 47 | 29 | 48 | 39 | 22 | 19 | 27 | 24 | 18 |
| Net Margin | Improving | 21.7% | 21.0% | 14.8% | 22.2% | 20.2% | 11.6% | 11.5% | 15.0% | 15.4% | 11.5% |
Key Takeaways
- Revenue from operations grew 17.85% YoY to ₹195.53 crore, driven largely by the Diagnostic Testing Services segment which contributed ₹182.41 crore.
- The company successfully executed a 2:1 bonus share issue during the quarter, allotting 10.61 crore new equity shares to eligible shareholders.
- Net profit for the quarter rose 48% YoY but saw a sequential decline primarily due to exceptional costs and a normalized revenue base compared to Q2.
- Reported an exceptional charge of ₹6.16 crore, including ₹4.20 crore for incremental gratuity impact due to new labor codes and ₹1.96 crore in capital restructuring costs.
- Operating margins show significant recovery from prior year levels, though they remain compressed compared to historical pre-acquisition highs.
- Subsidiary Nueclear Healthcare Limited (NHL) showed operational improvement with EBITDA of ₹3.93 crore and operating cash inflows for the nine-month period.
- Management noted that previous EPS figures have been restated to account for the bonus share allotment and stock option adjustments.
Management Guidance
Management is focused on maintaining low-cost leadership and leveraging synergies with digital pharmacy platforms following the PharmEasy acquisition. The emphasis remains on volume-led growth and stabilizing operating margins within the 25-30% range while optimizing the franchise-led model.
Sentiment Shift
Improving
The business is demonstrating a clear recovery in profitability and operational efficiency following the integration period post-acquisition, complemented by a shareholder-friendly bonus issue.
Outlook
The company expects to benefit from its pan-India centralized laboratory model and expanded test menu. Recovery in the Imaging segment and continued B2B dominance are expected to drive top-line momentum, although promoter-level pledging remains a key monitorable.
From the Annual Report (Key Quotes)
“The Company has presented such incremental impact as 'Exceptional Items'... accordingly the Exceptional Items includes of Rs. 4.01 Crores as incremental impact of Gratuity.”
“The shareholders... have approved for issuance of bonus equity shares in the ratio 2:1.”
“NHL has reported a positive earnings before interest tax and depreciation of Rs. 3.93 Crores.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Thyrocare Technologies Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.